The use of radiosensitizers recently emerged as a promising approach to circumvent the depth penetration limitations of photodynamic therapy of cancer and to enhance radiotherapeutical effects. A widely explored current strategy is based on complex nanoarchitectures that facilitate the transfer of energy harvested from X-ray radiation by scintillating nanoparticles to the surrounding photosensitizer molecules to generate reactive oxygen species, mostly singlet oxygen O₂(¹Δ_g). We describe an alternative approach aiming at a considerable simplification of the architecture. The presented nanoparticles, made of the luminescent octahedral molybdenum cluster compound (n-Bu₄N)₂[Mo₆I₈(OCOCF₃)₆], efficiently absorb X-rays due to the high content of heavy elements, leading to the formation of the excited triplet states that interact with molecular oxygen to produce O₂(¹Δ_g). The activity of the nanoparticles on HeLa cells was first investigated under UVA/blue-light irradiation in order to prove the biological effects of photosensitized O₂(¹Δ_g); there is no dark toxicity at micromolar concentrations, but strong phototoxicity in the nanomolar range. The nanoparticles significantly enhance the antiproliferative effect of X-ray radiation in vitro at lower concentration than for previously reported O₂(¹Δ_g) radiosensitizing systems and this effect is more pronounced on cancer HeLa cells than non-cancer MRC cells. The results demonstrate that the cluster-based radiosensitizers of O₂(¹Δ_g) have strong potential with respect to the enhancement of the efficacy of radiotherapy with exciting opportunities for cancer treatment.

Various host cell factors facilitate critical steps in the HIV-1 replication cycle. One of these factors is myo-inositol hexaphosphate (IP6), which contributes to assembly of HIV-1 immature particles and helps maintain the well-balanced metastability of the core in the mature infectious virus. Using a combination of two in vitro methods to monitor assembly of immature HIV-1 particles and disassembly of the mature core-like structure, we quantified the contribution of IP6 and other small polyanion molecules to these essential steps in the viral life cycle. Our data showed that IP6 contributes substantially to increasing the assembly of HIV-1 immature particles. Additionally, our analysis confirmed the important role of two HIV-1 capsid lysine residues involved in interactions with IP6. We found that myo-inositol hexasulphate also stabilized the HIV-1 mature particles in a concentration-dependent manner, indicating that targeting this group of small molecules may have therapeutic potential.

Due to the high number of drug-resistant HIV-1 mutants generated by highly active antiretroviral therapy (HAART), there is continuing demand for new types of inhibitors. Both the assembly of the Gag polyprotein into immature and mature HIV-1 particles are attractive candidates for the blocking of the retroviral life cycle. Currently, no therapeutically-used assembly inhibitor is available. One possible explanation is the lack of a reliable and simple assembly inhibitor screening method. To identify compounds potentially inhibiting the formation of both types of HIV-1 particles, we developed a new fluorescent high-throughput screening assay. This assay is based on the quantification of the assembly efficiency in vitro in a 96-well plate format. The key components of the assay are HIV-1 Gag-derived proteins and a dual-labelled oligonucleotide, which emits fluorescence only when the assembly of retroviral particles is inhibited. The method was validated using three (CAI, BM2, PF74) reported assembly inhibitors.

Ameloblastin (Ambn) as an intrinsically disordered protein (IDP) stands for an important role in the formation of enamel—the hardest biomineralized tissue commonly formed in vertebrates. The human ameloblastin (AMBN) is expressed in two isoforms: full-length isoform I (AMBN ISO I) and isoform II (AMBN ISO II), which is about 15 amino acid residues shorter than AMBN ISO I. The significant feature of AMBN—its oligomerization ability—is enabled due to a specific sequence encoded by exon 5 present at the N-terminal part in both known isoforms. In this study, we characterized AMBN ISO I and AMBN ISO II by biochemical and biophysical methods to determine their common features and differences. We confirmed that both AMBN ISO I and AMBN ISO II form oligomers in in vitro conditions. Due to an important role of AMBN in biomineralization, we further addressed the calcium (Ca²⁺)-binding properties of AMBN ISO I and ISO II. The binding properties of AMBN to Ca²⁺ may explain the role of AMBN in biomineralization and more generally in Ca²⁺ homeostasis processes.